×

FDA to miss deadline on Savara’s rare lung disease drug approval

By Thomson Reuters Nov 20, 2026 | 8:12 AM

Nov 20 (Reuters) – Drug developer Savara said on Friday the US FDA would not meet its November 22 deadline ​to decide whether to approve the ‌company’s treatment for a rare lung disease, dealing a setback to the biotech firm.

Shares of the company were down 16% in premarket trading.

• The ‌US ​Food and Drug Administration ⁠did not provide ⁠a new date for a decision, Savara said, adding that its application for approval remains under review

• The company is seeking ​approval of its experimental drug, molgramostim, for autoimmune pulmonary alveolar proteinosis (PAP), a ⁠rare condition in which ⁠material builds up in the lungs, ​making it harder for patients to breathe

• ​Molgramostim is designed to help immune cells ‌in the lungs clear that material. The drug is delivered through a nebulizer

• The FDA had previously extended its review by ⁠three months to assess additional information submitted by Savara. At the time, the company said the ⁠regulator had ‌not identified any safety, effectiveness ⁠or manufacturing concerns

• There are ​currently ‌no FDA-approved treatments for autoimmune ​PAP. Available ⁠care includes whole-lung lavage, an invasive procedure performed under general anesthesia in which the lungs are repeatedly washed to remove the buildup

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by ​Diti Pujara)